EU Clinical Trials Regulation (CTR) Final Transition Approaches: January 30, 2025 CTIS Cutoff
With the three-year transition period under Regulation (EU) No 536/2014 ending on January 30, 2025, clinical trial sponsors are completing the final wave of multilingual dossier migrations from EudraCT into the Clinical Trials Information System (CTIS).
The End of the Three-Year Directive-to-Regulation Transition
On January 30, 2025, the three-year transitional period established under the EU Clinical Trials Regulation (Regulation (EU) No 536/2014) comes to a definitive close. Any ongoing multinational clinical trial originally authorized under the legacy Clinical Trials Directive (2001/20/EC) that has at least one active site in the EEA beyond January 30, 2025 must be formally transitioned and authorized within the Clinical Trials Information System (CTIS).
Harmonizing Consolidated Protocols and Patient-Facing Translations
Transitioning legacy trials requires sponsors to consolidate protocol amendments across participating Member States and upload harmonized Part I scientific documentation alongside localized Part II patient-facing documents (ICFs, patient cards, and investigator brochures). Specialized medical translation teams working under ISO 17100 and ISO 18587 help pharmaceutical sponsors reconcile historical country-specific amendments and meet mandatory plain-language Lay Summary requirements within CTIS.
Executive Takeaways for Global Enterprises
- Key Insight: All ongoing EU clinical trials must be transitioned to CTIS under Regulation (EU) No 536/2014 by January 30, 2025.
- Key Insight: Consolidated clinical protocols and Part II patient documents require synchronized updates across Member State languages.
- Key Insight: Plain-language Lay Summaries of clinical trial results remain mandatory in all official EU languages of participating countries.
Benötigen Sie zertifizierte mehrsprachige Übersetzungen, beglaubigte Fachübersetzungen oder ISO-konforme Lokalisierung für Ihre internationalen Projekte? Fordern Sie ein kostenloses individuelles Angebot von Alphatrad an und erhalten Sie innerhalb von 24 Stunden eine detaillierte Rückmeldung.
Editorial & Copyright Attribution Note: This industry analysis has been independently synthesized and adapted by Alphatrad’s editorial team based on verified regulatory documentation and industry research originally published by European Medicines Agency (EMA) – Clinical Trials Information System. For the original publication and primary documentation, please consult:
Source: https://www.ema.europa.eu/en/human-regulatory-overview/research-development/clinical-trials-human-medicines/clinical-trials-regulation
Hinterlassen Sie einen Kommentar
Wollen Sie an der Diskussion teilnehmen?Wir freuen uns über ihren Beitrag!